Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-Cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer

23 December 2019, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Development of specific molecular probes holds great promise for early diagnosis of aggressive prostate cancer (PCa). Here, 2-[3-(1,3-dicarboxypropyl) ureido] pentanedioic acid (DUPA)-conjugated ligand and bis-isoindigo-based polymer (BTII) are synthesized to formulate semiconducting polymer nanoparticles (BTII-DUPA SPN) as a prostate-specific membrane antigen (PSMA)-targeted probe for PCa imaging in the NIR-II window. Insights into the interaction of the imaging probes with the biological targets from single-cell to whole-organ levels are obtained by transient absorption microscopy (TAM) and photoacoustic tomography (PAT). The targeting mechanism, kinetics, and specificity of BTII-DUPA SPN to PSMA-positive PCa cells are revealed at cellular level with TAM. At the organ level, PAT imaging of BTII-DUPA SPN in the NIR-II window demonstrates superior penetration depth and imaging contrast. By intravenous administration, BTII-DUPA SPN demonstrates selective accumulation and retention in the PSMA-positive tumor, allowing noninvasive PAT detection of PSMA overexpressing PCa. The distribution of nanoparticles at tissue level is further analyzed through TAM. These results collectively demonstrate a new SPN for targeted cancer detection by TAM and PAT imaging.


Semiconducting polymer nanoparticle
prostate cancer
transient absorption microscopy
photoacoustic tomography

Supplementary materials

DUPA v5 SI text


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.